Form 8-K · Current Report · Filed 2024-11-04
Revvity, Inc. Reports Third Quarter 2024 Financial Results
Revvity, Inc. announced financial results for the third quarter of 2024, reporting revenue of $684 million, GAAP EPS of $0.77, and adjusted EPS of $1.28. The company beat earnings expectations, raised its full-year adjusted EPS guidance to a range of $4.83 to $4.87, and authorized a new $1 billion share repurchase program. Press release details are furnished as Exhibit 99.1.
- Filer
- Revvity Inc. RVTY · NYSE
- Filed
- Accession
- 0000031791-24-000026
- CIK
- 0000031791
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$121.04
Next session
+4.1%
Since filing
+21.2%
Latest close
$146.73
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from RVTY reporting the same item, with the next session's move:
Exhibits (1)
About Revvity Inc.
Revvity Inc. is a health science tools and diagnostics company that provides end-to-end solutions for research, development, testing, and clinical use. The company operates through two main segments: Life Sciences and Diagnostics, serving customers across pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and government organizations. Its portfolio includes reagents, consumables, assays, instruments, software, and specialized services that support workflows from discovery through diagnosis. Revvity focuses on areas such as translational multi-omics, biomarker identification, imaging, screening, detection, informatics, reproductive health, immunodiagnostics, and genomic testing. It also supports applications in rare disease testing, newborn screening, hereditary cancer, and broader clinical laboratory services. Based in Waltham, Massachusetts, Revvity plays an important role in the healthcare and life sciences ecosystem by helping researchers, clinicians, and laboratories generate and analyze data across a wide range of scientific and diagnostic applications.
Never miss another RVTY filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.